Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.

Finasteride: Mechanism, Approved Label, and Topical Literature

Por Benn Bluestein-Veyra, M.Sc. en Química Orgánica · Actualizado el 1 de octubre de 2026

Finasteride is a competitive inhibitor of type II 5-alpha-reductase, the enzyme that converts testosterone to dihydrotestosterone in the hair follicle and the prostate.^[1] An approved oral product carries an FDA label whose indication is male pattern hair loss in men, no topical finasteride product is FDA-approved, and in April 2025 the FDA alerted providers, compounders and consumers to adverse event reports associated with compounded topical products.^[1][2] This page sets out the mechanism, what the label states, what the topical literature reports, and what the agency has said, in that order.

It is an evidence reference for professional education. The compounded hair and scalp formulations page on this site lists the topical solutions the 503A pharmacy partner can prepare to prescription and how each is dated; the oral tablet is an approved product dispensed against an ordinary prescription, and this page says nothing about which a prescriber should choose.

Finasteride blocks the enzyme isoform that sits in the scalp follicle

Testosterone is converted to dihydrotestosterone by 5-alpha-reductase, which exists as two principal isoforms. Type I predominates in sebaceous glands and skin; type II predominates in the prostate and in the dermal papilla of scalp hair follicles. Finasteride inhibits type II selectively, and the approved label describes a reduction in scalp and serum dihydrotestosterone as its pharmacodynamic effect.^[1]

The follicle connection runs through the dermal papilla, the cluster of mesenchymal cells at the base of each follicle that regulates the growth cycle. In androgenetic alopecia the papilla of a susceptible follicle responds to dihydrotestosterone by shortening the growth phase over successive cycles until the follicle miniaturizes, which is why the pharmacology of the enzyme is discussed in the literature in the context of that condition rather than of hair biology in general.^[3]

The papilla calls each growth phase through Wnt signaling, which the 2013 review by Lim and Nusse in Cold Spring Harbor Perspectives in Biology describes.^[4] In balding dermal papilla cells, androgen exposure has been reported in vitro to suppress Wnt signaling and to induce the Wnt inhibitor DKK-1.^[5][6] A currency exchange is a fair analogy for the sequence: testosterone arrives, the enzyme converts it, and the follicle is paid in dihydrotestosterone.

The selectivity for type II also explains the drug’s history. Finasteride was developed first for the prostate, and the one-milligram hair strength and the five-milligram prostate strength are the same molecule at different exposures.

The approved oral label states who, how long, and what to watch

The approved one-milligram oral product is indicated, in the words of its label, for male pattern hair loss in men only.^[1] The label states that daily use for three months or more is generally necessary before benefit is observed, that continued use is recommended to sustain benefit, and that the product is not indicated for women or children. It carries contraindications in pregnancy, a warning about exposure of pregnant women to crushed or broken tablets, and a description of its effect on prostate-specific antigen measurements.^[1]

The label was revised in 2012 to describe sexual adverse reactions that persisted after discontinuation, and the current prescribing information lists depression and suicidal ideation among reported adverse events.^[1][7] Those sections are reproduced in full on DailyMed, which is linked below, and they are a prescriber matter. A supplier can state what the label says and where to read it; the counseling conversation belongs to the prescriber.

A five-milligram oral tablet also exists and is approved for benign prostatic hyperplasia; it is outside the scope of this page, which describes only the one-milligram label, because that is the one whose indication is hair.

Use in women sits outside the approved label. Iamsumang and colleagues reviewed the evidence for finasteride in female pattern hair loss in 2020,^[8] and the European S3 guideline states its own position on women.^[9] This page reports both sources and resolves neither question.

The oral tablet has meta-analyses, guidelines and network rankings behind it

The 2017 systematic review and meta-analysis by Adil and Godwin in the Journal of the American Academy of Dermatology pooled randomized trials of the three most studied interventions for androgenetic alopecia and reported that oral finasteride, topical minoxidil and low-level laser light each outperformed placebo on hair count.^[10] It is the reference most often cited for the position that the approved actives have trial evidence behind them, and it is cited here for that reason.

A 2022 network meta-analysis by Gupta and colleagues in JAMA Dermatology ranked minoxidil and the 5-alpha-reductase inhibitors against one another in men.^[11] A 2025 network meta-analysis by the same group in the Journal of Cosmetic Dermatology repeated the comparison across 33 eligible studies.^[12] Network rankings give the comparative picture that single-agent trials cannot.

Starace and colleagues compared topical minoxidil, oral finasteride and topical finasteride in a 2024 retrospective cohort of postmenopausal women.^[13] Oral finasteride ranked highest across the four endpoints, and the authors reported no statistically significant differences between the three regimens.^[13] They concluded that more studies are needed.

The European S3 guideline by Kanti and colleagues, published in 2018, gave oral finasteride a formal evidence-graded recommendation in men.^[9] A 2025 Canadian consensus by Landells and colleagues restated the specialist approach.^[14] Devjani and colleagues in Drugs in 2023 and Nestor and colleagues in 2021 supply current therapy updates, and Nestor weighs compliance, cost and ethics beside efficacy.^[3][15]

The topical literature is real, and approval still rests with the FDA

The rationale for topical finasteride is that scalp dihydrotestosterone can be lowered with less systemic exposure than the oral tablet produces, and Suchonwanit and colleagues reviewed that rationale in 2022 before the phase III data published.^[16] A 2022 phase III randomized controlled trial by Piraccini and colleagues in the Journal of the European Academy of Dermatology and Venereology studied a 0.25% finasteride spray solution in men with androgenetic alopecia and reported target-area hair count gains over vehicle at 24 weeks, with serum dihydrotestosterone reductions smaller than those reported for the oral tablet.^[17]

A 2025 systematic review and meta-analysis in Frontiers in Medicine pooled seven randomized trials, 396 participants in total, comparing a mixed minoxidil and finasteride solution with minoxidil solution alone in men, and reported that the combination outperformed minoxidil alone on hair density, hair diameter and global photographic assessment.^[18] The compounded solutions on this site pair 0.1% finasteride with 5% minoxidil, a lower finasteride concentration than the phase III spray studied. That difference is one of several reasons a compounded product needs its own evidence before a trial result can be applied to it.

Neither finding creates an approved product. No topical finasteride formulation is FDA-approved, and a compounded topical solution is prepared under section 503A to an individual prescription without FDA review of its safety, effectiveness or quality.^[19] The FDA’s own questions and answers on compounding, linked below, say exactly that. The literature describes what was studied, and the product keeps its compounded status.

The FDA alert concerns counseling as much as pharmacology

The alert also recorded that many of the consumers in those reports stated they had not been told of the potential risks by the prescriber, and in some cases had been told the topical form carried none.^[2] That is the sentence in the alert with the most operational content for a practice, because it describes a counseling failure rather than a pharmacological one, and the alert is linked in full in the sources below.

Two pharmacovigilance analyses of the FDA Adverse Event Reporting System were published in 2025. Zhong and colleagues in PLoS One analyzed reports from 2004 to April 2024 across organ systems,^[20] and Thaibah and colleagues in Pharmaceuticals examined suicidality signals specifically.^[21] Gupta and colleagues evaluated the depression and suicide question separately in the Journal of Cosmetic Dermatology.^[22]

All three rest on spontaneous reports rather than trial data, and the study design badge beside each citation below says so. The European Medicines Agency added suicidal ideation to the product information for finasteride in May 2025, together with a patient card to accompany the product.

Every page on this site that discusses topical finasteride cites the alert, and the compounded hair and scalp formulations page describes the topical solutions by their composition and dating only.

The oral tablet and the topical solutions sit in separate regimes

Finasteride reaches a practice in two materially different forms. The oral tablet is an FDA-approved product dispensed against an ordinary prescription. The topical form appears as a fraction of a percent in two minoxidil solutions that our 503A pharmacy partner, licensed by the Texas State Board of Pharmacy, prepares to an individual prescription.

Each topical solution carries a short beyond-use date and a single-unit ceiling per fill. Compounded preparations are dispensed only in the states where the pharmacy holds a non-resident license, and the state hair guides on this site list those states.

The oral tablet and the topical solution are different products with different dating, and a practice that orders both holds them as separate line items. Which form, if either, suits a given patient is a prescribing decision that this page does not take part in.

Finasteride’s evidence and its warnings arrived together

The oral tablet has an approved label, pooled randomized trials and network rankings behind it. It also has a 2012 label revision, 2025 safety analyses and a European product-information update naming persistent sexual and psychiatric adverse events.

The topical form has a phase III trial and a meta-analysis of combination solutions behind it. It also has an FDA alert whose central finding is that patients were not told what the oral literature already said. A practice that holds both halves of the record keeps the oral and topical line items apart and points every patient to the approved label and the alert.